MEDS Stock Overview
PT Hetzer Medical Indonesia Tbk manufactures and sells masks with 4D designs in Indonesia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PT Hetzer Medical Indonesia Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp50.00 |
| 52 Week High | Rp122.00 |
| 52 Week Low | Rp50.00 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -51.92% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDS | ID Medical Equipment | ID Market | |
|---|---|---|---|
| 7D | 0% | 3.1% | 0.6% |
| 1Y | -51.9% | -9.6% | 1.7% |
Return vs Industry: MEDS underperformed the ID Medical Equipment industry which returned -7.8% over the past year.
Return vs Market: MEDS underperformed the ID Market which returned 2.6% over the past year.
Price Volatility
| MEDS volatility | |
|---|---|
| MEDS Average Weekly Movement | 0% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in ID Market | 12.1% |
| 10% least volatile stocks in ID Market | 2.3% |
Stable Share Price: MEDS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MEDS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 24 | Yenny Marlina | www.evoplusmed.com |
PT Hetzer Medical Indonesia Tbk manufactures and sells masks with 4D designs in Indonesia. It offers surgical, hijab series, kids, and other masks, as well as antiseptic hand rub products. The company was founded in 2010 and is based in Cimahi, Indonesia.
PT Hetzer Medical Indonesia Tbk Fundamentals Summary
| MEDS fundamental statistics | |
|---|---|
| Market cap | Rp78.13b |
| Earnings (TTM) | -Rp3.57b |
| Revenue (TTM) | Rp22.72b |
3.4x
P/S Ratio-21.9x
P/E RatioIs MEDS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDS income statement (TTM) | |
|---|---|
| Revenue | Rp22.72b |
| Cost of Revenue | Rp10.30b |
| Gross Profit | Rp12.43b |
| Other Expenses | Rp16.00b |
| Earnings | -Rp3.57b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.29 |
| Gross Margin | 54.68% |
| Net Profit Margin | -15.71% |
| Debt/Equity Ratio | 12.2% |
How did MEDS perform over the long term?
See historical performance and comparison